In a phase II study, Lisberg et al. highlighted the absence of response to pembrolizumab as first line approach in advanced stage PD-L1 positive EGFR-mutant NSCLC patients naïve to TKI administration [28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.